Health ❯Healthcare ❯Clinical Trials ❯Drug Efficacy

Patient Outcomes

Metsera’s Obesity Drug Posts 14% Placebo-Adjusted Weight Loss, Bolstering Pfizer Buyout Case

Topline results strengthen the case for a late-2025 Phase 3 start under Pfizer ownership.

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

FDA Approves Journavx, First Non-Opioid Painkiller in Over 20 Years

Zepbound Outperforms Wegovy in Weight Loss Clinical Trial

First New Asthma and COPD Treatment in 50 Years Shows Promise